FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006370082> ?p ?o ?g. }

• W2006370082 endingPage "131" @default.
• W2006370082 startingPage "107" @default.
• W2006370082 abstract "Age-related macular degeneration (AMD) is a leading cause of blindness in people aged ≥50 years. Wet AMD in particular has a major impact on patient quality of life and imposes substantial burdens on healthcare systems. This systematic review examined the cost-effectiveness data for current therapeutic options for wet AMD. PubMed and EMBASE databases were searched for all articles reporting original cost-effectiveness analyses of wet AMD treatments. The Centre for Reviews and Dissemination and Cochrane Library databases were searched for all wet AMD health technology assessments (HTAs). Overall, 44 publications were evaluated in full and included in this review. A broad range of cost-effectiveness analyses were identified for the most commonly used therapies for wetAMD(pegaptanib, ranibizumab and photodynamic therapy [PDT] with verteporfin). Three studies evaluated the cost effectiveness of bevacizumab in wet AMD. A small number of analyses of other treatments, such as laser photocoagulation and antioxidant vitamins, were also found. Ranibizumab was consistently shown to be cost effective for wet AMD in comparison with all the approved wet AMD therapies (four of the five studies identified showed ranibizumab was cost effective vs usual care, PDT or pegaptanib); however, there was considerable variation in the methodology for cost-effectiveness modelling between studies. Findings from the HTAs supported those from the PubMed and EMBASE searches; of the seven HTAs that included ranibizumab, six (including HTAs for Australia, Canada and the UK) concluded that ranibizumab was cost effective for the treatment of wet AMD; most compared ranibizumabwith PDT and/or pegaptanib. By contrast, HTAs at best generally recommended pegaptanib or PDT for restricted use in subsets of patients with wet AMD. In the literature analyses, pegaptanib was found to be cost effective versus usual/best supportive care (including PDT) or no treatment in one of five studies; the other four studies found pegaptanib was of borderline cost effectiveness depending on the stage of disease and time horizon. PDT was shown to be cost effective versus usual/best supportive care or no treatment in five of nine studies; two studies showed that PDT was of borderline cost effectiveness depending on baseline visual acuity, and two showed that PDT was not cost effective. We identified no robust studies that properly evaluated the cost effectiveness of bevacizumab in wet AMD." @default.
• W2006370082 created "2016-06-24" @default.
• W2006370082 creator A5007482776 @default.
• W2006370082 creator A5011236728 @default.
• W2006370082 creator A5032135957 @default.
• W2006370082 creator A5060054698 @default.
• W2006370082 creator A5072989934 @default.
• W2006370082 date "2011-02-01" @default.
• W2006370082 modified "2023-09-23" @default.
• W2006370082 title "Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration" @default.
• W2006370082 cites W1500347834 @default.
• W2006370082 cites W1595972774 @default.
• W2006370082 cites W1601975653 @default.
• W2006370082 cites W1802218256 @default.
• W2006370082 cites W1955886324 @default.
• W2006370082 cites W1966486839 @default.
• W2006370082 cites W1967893571 @default.
• W2006370082 cites W1972997098 @default.
• W2006370082 cites W1973250774 @default.
• W2006370082 cites W1975926216 @default.
• W2006370082 cites W1976851897 @default.
• W2006370082 cites W1981972240 @default.
• W2006370082 cites W1986807047 @default.
• W2006370082 cites W1991583017 @default.
• W2006370082 cites W1993218617 @default.
• W2006370082 cites W1995781156 @default.
• W2006370082 cites W1997357305 @default.
• W2006370082 cites W2002020452 @default.
• W2006370082 cites W2009734383 @default.
• W2006370082 cites W2013584137 @default.
• W2006370082 cites W2014466117 @default.
• W2006370082 cites W2016040594 @default.
• W2006370082 cites W2034029819 @default.
• W2006370082 cites W2039446733 @default.
• W2006370082 cites W2042321005 @default.
• W2006370082 cites W2044558504 @default.
• W2006370082 cites W2066334011 @default.
• W2006370082 cites W2069110097 @default.
• W2006370082 cites W2070716505 @default.
• W2006370082 cites W2073005444 @default.
• W2006370082 cites W2074620139 @default.
• W2006370082 cites W2075984382 @default.
• W2006370082 cites W2077891356 @default.
• W2006370082 cites W2085380987 @default.
• W2006370082 cites W2085442615 @default.
• W2006370082 cites W2085712747 @default.
• W2006370082 cites W2091665329 @default.
• W2006370082 cites W2095251825 @default.
• W2006370082 cites W2095456059 @default.
• W2006370082 cites W2098305436 @default.
• W2006370082 cites W2103699088 @default.
• W2006370082 cites W2107057433 @default.
• W2006370082 cites W2108921960 @default.
• W2006370082 cites W2111157054 @default.
• W2006370082 cites W2119756876 @default.
• W2006370082 cites W2124415048 @default.
• W2006370082 cites W2127937793 @default.
• W2006370082 cites W2142693543 @default.
• W2006370082 cites W2150815840 @default.
• W2006370082 cites W2152081338 @default.
• W2006370082 cites W2166334471 @default.
• W2006370082 cites W2463515528 @default.
• W2006370082 cites W2463967878 @default.
• W2006370082 cites W2915852396 @default.
• W2006370082 doi "https://doi.org/10.2165/11585520-000000000-00000" @default.
• W2006370082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21244102" @default.
• W2006370082 hasPublicationYear "2011" @default.
• W2006370082 type Work @default.
• W2006370082 sameAs 2006370082 @default.
• W2006370082 citedByCount "42" @default.
• W2006370082 countsByYear W20063700822012 @default.
• W2006370082 countsByYear W20063700822013 @default.
• W2006370082 countsByYear W20063700822014 @default.
• W2006370082 countsByYear W20063700822015 @default.
• W2006370082 countsByYear W20063700822016 @default.
• W2006370082 countsByYear W20063700822017 @default.
• W2006370082 countsByYear W20063700822018 @default.
• W2006370082 countsByYear W20063700822019 @default.
• W2006370082 countsByYear W20063700822020 @default.
• W2006370082 countsByYear W20063700822022 @default.
• W2006370082 crossrefType "journal-article" @default.
• W2006370082 hasAuthorship W2006370082A5007482776 @default.
• W2006370082 hasAuthorship W2006370082A5011236728 @default.
• W2006370082 hasAuthorship W2006370082A5032135957 @default.
• W2006370082 hasAuthorship W2006370082A5060054698 @default.
• W2006370082 hasAuthorship W2006370082A5072989934 @default.
• W2006370082 hasBestOaLocation W20063700822 @default.
• W2006370082 hasConcept C112930515 @default.
• W2006370082 hasConcept C118487528 @default.
• W2006370082 hasConcept C119767625 @default.
• W2006370082 hasConcept C126322002 @default.
• W2006370082 hasConcept C177713679 @default.
• W2006370082 hasConcept C2776403814 @default.
• W2006370082 hasConcept C2776478404 @default.
• W2006370082 hasConcept C2776694085 @default.
• W2006370082 hasConcept C2776738588 @default.
• W2006370082 hasConcept C2777512022 @default.
• W2006370082 hasConcept C2777802072 @default.

• next